Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HMPL-011 in Healthy Volunteers
NCT03860532Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Sep 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of HMPL-011 in inflammatory bowel disease (IBD) (3 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Peak Plasma Concentration (Cmax) of HMPL-011 tablets vs capsules in fasted States at 72 hours, Peak Plasma Concentration (Cmax) of HMPL-011 tablets vs capsules in fed States at 72 hours and 3 more. Started Sep 2011; status: completed.
02
Drugs
HMPL-011
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT03860532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03860532.